Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154220 | 0.89 | ALOX12 (0.42) | ALOX12ALOX15KCNH2TRPV1CYP19A1 | |
| SCHEMBL12055312 | 0.88 | ALOX12 (0.44) | ALOX12ALOX15KCNH2TRPV1CYP19A1 | |
| SCHEMBL10077875 | 0.83 | ALOX12 (0.43) | ALOX12ALOX15KCNH2TRPV1CYP19A1 | |
| SCHEMBL242978 | 0.78 | CYP19A1 (0.61) | ALOX12ALOX15KCNH2TRPV1CYP19A1 | |
| SCHEMBL2604717 | 0.78 | CYP19A1 (0.64) | ALOX12ALOX15KCNH2TRPV1CYP19A1 | |
| SCHEMBL4432673 | 0.77 | CYP19A1 (0.56) | ALOX12ALOX15KCNH2TRPV1CYP19A1 | |
| SCHEMBL133522 | 0.75 | LMNA (0.36) | LMNAGLAKDM4ENPSR1ALDH1A1 | |
| SCHEMBL329883 | 0.74 | ALOX12 (0.47) | ALOX12ALOX15KCNH2TRPV1CYP19A1 | |
| SCHEMBL3956230 | 0.72 | ALOX12 (0.46) | ALOX12ALOX15KCNH2TRPV1CYP19A1 | |
| SCHEMBL3957591 | 0.70 | ALOX12 (0.53) | ALOX12ALOX15KCNH2TRPV1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | TNF, PTGES, NFKBIA | ALOX12 61/4885ALOX15 72/4885KCNH2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.